Summary & Overview
CPT 0232U: Genomic Unity CSTB Analysis, PCR‑free Whole Genome Sequencing
CPT code 0232U designates the Genomic Unity® CSTB Analysis, a Proprietary Laboratory Analyses (PLA) test by Variantyx Inc. that uses PCR-free whole genome sequencing of blood or saliva to evaluate the cystatin B (CSTB) gene for variants linked to progressive myoclonic epilepsy type 1A (Unverricht–Lundborg syndrome). As a PLA code, 0232U maps to a single manufacturer-specific assay, which matters for coverage determination, billing consistency, and laboratory reimbursement nationally.
Key payers in this analysis include Aetna, Blue Cross Blue Shield, Cigna Health, UnitedHealthcare, and Medicare. Readers will find national-level context about the code's clinical purpose, typical site of service, and implications for laboratory and payer interactions. The publication outlines benchmark considerations for PLA-coded tests, summarizes clinical context for CSTB sequencing, and highlights policy-relevant elements such as PLA coding implications for unique proprietary assays and the expected settings for specimen collection and laboratory processing.
Data not available in the input for associated taxonomies, ICD-10 diagnoses, related codes, and detailed payer coverage policies.
Billing Code Overview
CPT code 0232U is a Proprietary Laboratory Analyses (PLA) code assigned to the Genomic Unity® CSTB Analysis manufactured by Variantyx Inc. The test evaluates the cystatin B (CSTB) gene for genetic variants associated with conditions such as progressive myoclonic epilepsy type 1A (Unverricht–Lundborg syndrome). The assay uses a blood or saliva specimen and is performed on a PCR-free whole genome sequencing (WGS) platform with algorithmic data analysis.
Service type: Genetic sequencing / molecular diagnostic testing
Typical site of service: Clinical laboratory (blood or saliva specimen collection in outpatient clinic, physician office, or specimen collection center; laboratory processing in a specialized molecular diagnostics lab)
Clinical & Coding Specifications
Clinical Context
A patient (adult or pediatric) with progressive myoclonic seizures or a family history of Unverricht–Lundborg syndrome presents to a neurologist or geneticist for diagnostic evaluation. The clinician documents refractory myoclonic epilepsy, action- and stimulus-sensitive myoclonus, cognitive decline, and/or early-onset generalized tonic–clonic seizures and orders a targeted genomic test. A blood or saliva specimen is collected in the outpatient clinic or infusion center and sent to Variantyx for the proprietary Genomic Unity® CSTB Analysis. The laboratory performs PCR-free whole genome sequencing (WGS) with algorithmic analysis focused on the CSTB gene to identify pathogenic variants, repeat expansions, or other alterations relevant to progressive myoclonic epilepsy type 1A. Results are returned to the ordering clinician for integration into clinical diagnosis, genetic counseling, family cascade testing, and treatment planning. Typical sites of service include outpatient physician offices, specialty neurology clinics, and commercial genetic testing laboratories; specimen collection may occur in-clinic or at a certified phlebotomy site.
Coding Specifications
| Modifier | Description | When to Use |
|---|---|---|
00 | Default/Standard - no modifier | Used when no other modifier applies and the service is billed normally. |